FY2018 3Q Consolidated Financial Overview (IFRS based)

CHUGAI PHARMACEUTICAL CO., LTD.
Executive Vice President and CFO
Toshiaki Itagaki

October 24, 2018

Innovation all for the patients
CHUGAI
Roche A member of the Roche group

Forward-Looking Statements

This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the "Company"). These statements reflect the Company's current analysis of existing information and trends. Actual results may differ from expectations based on risks and uncertainties that may affect the Company's businesses.

Note: Amounts shown in this report are rounded to the nearest 0.1 billion yen
Variance and % are calculated based on the amounts shown.

Innovation all for the patients
CHUGAI
Roche A member of the Roche group

3Q Results Summary

■ **Revenues: 426.4 billion yen (+38.8, +10.0% YoY)**

- Domestic sales excl. Tamiflu: despite impact from HIP revision, slight increase due to continued growth of sales of mainstay products (+0.9, +0.3%)
- Overseas sales: growth of Actemra and Alecensa export to Roche (+24.1, +32.7%)
- Royalties and other operating income: one-time income from transfer of long-listed products on HIP list, etc. (+14.8, +64.6%)

■ **Cost of sales / Operating expenses (Core basis)**

- Cost of sales: the ratio to sales improved due to a change in product sales mix, etc. (-0.9% points, from 50.9% to 50.0%)
- Operating expenses: overall increase mainly due to increase of research and development expenses (-5.5, +4.5%)

■ **Profits**

- IFRS results: operating profit 97.9 billion yen (+21.7, +28.5%)
  net income 70.9 billion yen (+13.0, +22.5%)
- Core results: operating profit 103.3 billion yen (+24.6, +31.3%)
  net income 74.6 billion yen (+14.9, +25.0%)
- Core EPS (JPY): 135.14 (+27.34 +25.4%)

Innovation all for the patients
CHUGAI
Roche A member of the Roche group

IFRS and Core Results Jan-Sep

(Billion JPY)	IFRS results 2018 Jan. - Sep.	Non-core items: Intangible assets	Non-core items: Others	Core results 2018 Jan. - Sep.
Revenues	**426.4**			**426.4**
Sales	388.7			388.7
Royalties and other operating income	37.7			37.7
Cost of sales	-195.0	+0.7		-194.3
Gross profit	**231.4**	**+0.7**		**232.1**
Operating expenses	**-133.5**	**+4.6**		**-128.9**
Marketing and distribution	-50.4			-50.4
Research and development	-70.9	+4.6		-66.3
General and administration	-12.2			-12.2
Operating profit	**97.9**	**+5.3**		**103.3**
Financing costs	-0.1			-0.1
Other financial income (expense)	-0.1			-0.1
Other expense	-2.1			-2.1
Profit before taxes	**95.6**	**+5.3**		**101.0**
Income taxes	-24.8	-1.6		-26.4
Net income	**70.9**	**+3.7**		**74.6**
Chugai shareholders	70.3	+3.7		74.0
Non-controlling interests	0.5			0.5

(Billions of JPY)

Non-Core items

Intangible assets:
- Amortization of intangible assets +0.9
- Impairment +4.4

Others:
- none

Core net income attributable to Chugai shareholders 74.0

(Millions of shares)

Weighted average number of shares and equity securities in issue used to calculate diluted earnings per share 548

(JPY)

Core EPS 135.14

Year on Year (Core)

Financial Overview Jan - Sep

Innovation all for the patients
CHUGAI
Roche A member of the Roche group

(Billions of JPY)	2017 Jan - Sep	vs. Revenues	2018 Jan - Sep	vs. Revenues	Growth	
Revenues	**387.6**		**426.4**		**+38.8**	**+10.0%**
Sales	364.8		388.7		+23.9	+6.6%
excl. Tamiflu	354.8		379.8		+25.0	+7.0%
Domestic	281.0		281.9		+0.9	+0.3%
Export to Roche	60.6		84.2		+23.6	+38.9%
Other overseas	13.2		13.7		+0.5	+3.8%
Tamiflu	10.0		8.9		-1.1	-11.0%
Ordinary	6.3		8.3		+2.0	+31.7%
Govt. stockpiles, etc.	3.7		0.5		-3.2	-86.5%
Royalties and other operating income	22.9		37.7		+14.8	+64.6%
Cost of sales	-185.6	47.9%	-194.3	45.6%	-8.7	+4.7%
Gross profit	**202.1**	**52.1%**	**232.1**	**54.4%**	**+30.0**	**+14.8%**
Operating expenses	-123.4	31.8%	-128.9	30.2%	-5.5	+4.5%
Operating profit	**78.7**	**20.3%**	**103.3**	**24.2%**	**+24.6**	**+31.3%**
Financing costs	-0.1		-0.1		0.0	0.0%
Other financial income (expense)	-0.2		-0.1		+0.1	-50.0%
Other Expenses	-1.1		-2.1		-1.0	+90.9%
Income taxes	-17.6		-26.4		-8.8	+50.0%
Net income	**59.7**	**15.4%**	**74.6**	**17.5%**	**+14.9**	**+25.0%**
EPS (JPY)	107.80		135.14		+27.34	+25.4%

(Billions of JPY)

Royalties and other operating income	+14.8
one-time income from transfer of long-listed products on HIP list, etc.	
Other financial income (expense)	+0.1
Exchange gains/losses	+0.1
Gains/Losses on derivatives (Gains/Losses on foreign exchange forward contracts)	+0.0
Other Expenses	-1.0
Settlement for transfer pricing taxation	

Cost of sales ratio vs. Sales

2017 Jan – Sep	2018 Jan – Sep
50.9%	50.0%

Market average exchange rate (JPY)

	2017 Jan – Sep	2018 Jan - Sep
1 CHF	113.73	112.79
1 EUR	124.33	130.93
1 USD	111.92	109.65
1 SGD	80.52	81.81

Year on Year

Sales (excl. Tamiflu) Jan - Sep

Innovation all for the patients
CHUGAI
Roche A member of the Roche group

Sales by Disease Area, Year on Year Comparisons



Sales by Products, Year on Year Changes





*) Details of HER2 franchise

Herceptin (20.6)	-4.0,	-16.3%
Perjeta (11.0)	+1.2,	+12.2%
Kadcyla (6.2)	+0.4,	+6.9%

( ): Actual sales in FY2018
%: Year-on-year percentage change

Innovation all for the patients
CHUGAI
Roche A member of the Roche group

Tamiflu Sales Trends

(Billions of JPY)	Fiscal Term Sales											
	FY2013		FY2014		FY2015		FY2016		FY2017		FY2018	
	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Sep
Ordinary	8.2											
		1.9	7.0									
				5.8	6.7							
						1.5	7.3					
								4.7	6.3			
										5.6	8.3	
												0.0
	10.1	**(-0.1)**	**12.9**	**(+2.8)**	**8.2**	**(-4.7)**	**12.0**	**(+3.8)**	**11.9**	**(-0.1)**	**8.3**	**(+2.0)**
Govt. Stockpiles etc.	0.8	0.1	0.1	0.1	0.0	0.0	0.0	1.5	1.9	3.1	0.1	0.4
	0.9	**(-1.0)**	**0.2**	**(-0.7)**	**0.0**	**(-0.2)**	**1.5**	**(+1.5)**	**5.0**	**(+3.5)**	**0.5**	**(-3.2)**
Total	**9.0**	**2.0**	**7.1**	**5.9**	**6.7**	**1.5**	**7.3**	**6.2**	**8.2**	**8.7**	**8.4**	**0.4**
	11.0	**(-1.0)**	**13.0**	**(+2.0)**	**8.2**	**(-4.8)**	**13.5**	**(+5.3)**	**16.9**	**(+3.4)**	**8.9**	**(-1.1)**

( ) Year on year

Season (from the second half of FY to the first half of the next FY)	
2012	**10.6**
2013	**9.0**
2014	**12.6**
2015	**8.7**
2016	**11.0**
2017	**14.0**

Year on Year (Core)

Operating Profit Jan - Sep



(Billions of JPY)	2017 Jan - Sep	2018 Jan - Sep	Growth
Revenues	**387.6**	**426.4**	**+38.8**
Cost of sales	-185.6	-194.3	-8.7
Gross profit	**202.1**	**232.1**	**+30.0**
of which Sales	179.2	194.4	+15.2
Royalties, etc.	22.9	37.7	+14.8
Marketing and distribution	-49.2	-50.4	-1.2
Research and development	-63.2	-66.3	-3.1
General and administration	-11.0	-12.2	-1.2
Operating profit	**78.7**	**103.3**	**+24.6**

Increase in gross profit from sales +15.2
Increase in export to Roche and improvement of cost of sales ratio to sales due to change in product sales mix, etc.

Increase in royalties and other operating income +14.8

Increase in marketing and distribution expenses -1.2
Increase in sales and marketing activities mainly for new products, and FX impact

Increase in research and development expenses -3.1
Progress of projects, etc.

Increase in general and administration expenses, etc. -1.2
Increase in various expenses, including enterprise tax and legal expenses

Innovation all for the patients
CHUGAI
Roche A member of the Roche group

Year on Year (Core)

Financial Overview Jul - Sep

(Billions of JPY)	2017 Jul - Sep	vs. Revenues	2018 Jul - Sep	vs. Revenues	Growth	
Revenues	**134.9**		**141.3**		**+6.4**	**+4.7%**
Sales	127.9		133.1		+5.2	+4.1%
excl. Tamiflu	126.1		132.7		+6.6	+5.2%
Domestic	97.9		99.2		+1.3	+1.3%
Export to Roche	23.7		28.9		+5.2	+21.9%
Other overseas	4.4		4.5		+0.1	+2.3%
Tamiflu	1.9		0.4		-1.5	-78.9%
Ordinary	0.0		0.0		0.0	0.0%
Govt. stockpiles, etc.	1.8		0.4		-1.4	-77.8%
Royalties and other operating income	6.9		8.2		+1.3	+18.8%
Cost of sales	-64.8	48.0%	-65.7	46.5%	-0.9	+1.4%
Gross profit	**70.1**	**52.0%**	**75.6**	**53.5%**	**+5.5**	**+7.8%**
Operating expenses	-41.7	30.9%	-44.0	31.1%	-2.3	+5.5%
Operating profit	**28.5**	**21.1%**	**31.6**	**22.4%**	**+3.1**	**+10.9%**
Financing costs	-0.0		-0.0		0.0	0.0%
Other financial income (expense)	0.0		-0.1		-0.1	-
Other Expenses	-0.7		-0.6		+0.1	-14.3%
Income taxes	-6.9		-8.9		-2.0	+29.0%
Net income	**20.9**	**15.5%**	**22.0**	**15.6%**	**+1.1**	**+5.3%**
EPS (JPY)	37.70		39.87		+2.17	+5.8%

Increase in gross profit from sales +4.2

Increase in export to Roche and improvement of cost of sales ratio to sales

Increase in royalties and other operating income +1.3

Increase in operating expenses -2.3

Increase in marketing and distribution -0.2

Increase in research and development -1.5

Progress of projects, etc.

Increase in general and administration, etc. -0.5

Cost of sales ratio vs. Sales

2017 Jul – Sep	2018 Jul – Sep
50.7%	49.4%

Market average exchange rate (JPY)

	2017 Jul – Sep	2018 Jul - Sep
1 CHF	115.33	113.32
1 EUR	130.36	129.66
1 USD	111.01	111.47
1 SGD	81.57	81.51

vs. Forecast (Core)

Financial Progress Jan - Sep

(Billions of JPY)	Actual 2018 Jan - Sep	Forecast on Feb. 1 2018 Jan - Dec	Forecast on Feb. 1 Progress	2017 Progress *
Revenues	**426.4**	**541.5**	**78.7%**	**72.6%**
Sales	388.7	498.5	78.0%	73.1%
excl. Tamiflu	379.8	492.9	77.1%	73.5%
Domestic	281.9	374.8	75.2%	72.3%
Export to Roche	84.2	99.6	84.5%	79.3%
Other overseas	13.7	18.5	74.1%	74.6%
Tamiflu	8.9	5.6	158.9%	59.2%
Royalties and other operating income	37.7	43.0	87.7%	65.6%
Cost of sales	-194.3	-252.0	77.1%	73.4%
Gross profit	**232.1**	**289.5**	**80.2%**	**71.8%**
Operating expenses	-128.9	-181.5	71.0%	69.3%
Operating profit	**103.3**	**108.0**	**95.6%**	**76.3%**
EPS (JPY)	135.14	147.00	91.9%	77.7%

* Jan – Sep progress versus Jan – Dec

Cost of sales ratio vs. Sales

2018 Jan – Sep Actual	2018 Jan – Dec Forecast
50.0%	50.6%

Exchange rate (JPY)

	2018 Jan – Sep Actual*	2018 Jan – Dec Assumption
1CHF	112.79	115.00
1EUR	130.93	133.00
1USD	109.65	111.00
1SGD	81.81	84.00

* Market average exchange rate for the period of Jan – Sep.

vs. Forecast (Core)

Innovation all for the patients
CHUGAI
Roche A member of the Roche group

Sales Progress (excl. Tamiflu) Jan – Sep

(Billions of JPY)	Actual 2018 Jan - Sep	Forecast 2018 Jan - Dec	Progress	2017 Progress *1
Sales excl. Tamiflu	**379.8**	**492.9**	**77.1%**	**73.5%**
Domestic	**281.9**	**374.8**	**75.2%**	**72.3%**
Oncology	**163.3**	**218.2**	**74.8%**	**72.4%**
Avastin	69.5	92.0	75.5%	72.6%
HER2 Franchise	37.8	49.5	76.4%	72.6%
Herceptin	20.6	26.6	77.4%	73.2%
Perjeta	11.0	14.6	75.3%	72.1%
Kadcyla	6.2	8.3	74.7%	72.5%
Rituxan	17.0	23.4	72.6%	72.2%
Alecensa	14.7	22.7	64.8%	70.1%
Xeloda	9.2	12.6	73.0%	73.0%
Tarceva	6.5	9.8	66.3%	73.3%
Tecentriq *2	5.0	3.1	161.3%	-
Alaglio	0.2	0.7	28.6%	-
Gazyva *4	0.1	0.6	16.7%	-
Zelboraf	0.0	0.1	0.0%	100.0%
Bone and Joint	**72.4**	**97.1**	**74.6%**	**71.9%**
Actemra	27.4	35.2	77.8%	71.3%
Edirol	23.4	31.7	73.8%	71.3%
Bonviva	6.8	9.9	68.7%	71.3%
Suvenyl	5.7	8.3	68.7%	72.7%

(Billions of JPY)	Actual 2018 Jan - Sep	Forecast 2018 Jan - Dec	Progress	2017 Progress *1
Renal	**26.3**	**35.3**	**74.5%**	**72.0%**
Mircera	16.6	23.5	70.6%	72.0%
Oxarol	5.3	5.8	91.4%	72.0%
Others	**19.9**	**24.2**	**82.2%**	**73.6%**
CellCept	6.6	8.5	77.6%	71.9%
Hemlibra *3	1.5	1.4	107.1%	-
Overseas	**97.9**	**118.1**	**82.9%**	**78.5%**
Actemra	64.4	73.0	88.2%	80.0%
Export to Roche	63.1	71.4	88.4%	80.1%
Alecensa	19.5	26.4	73.9%	73.4%
Export to Roche	19.1	26.3	72.6%	73.4%
Neutrogin	8.7	12.0	72.5%	74.8%
Hemlibra	2.0	2.0	100.0%	90.3%

*1 Jan - Sep progress versus Jan – Dec.
*2 Forecast for Tecentriq was officially announced on April 24, 2018.
*3 Forecast for Hemlibra (domestic sales) was officially announced on July 26, 2018
*4 Forecast for Gazyva was officially announced on October 24, 2018

Innovation all for the patients
CHUGAI
Roche A member of the Roche group

vs. Forecast (Core)

Impact from Foreign Exchange

(Billions of JPY)	FX impact Jan – Sep 2018 (FX impact vs. Assumption)	
Revenues	**-0.6**	
	Sales	-0.3
	Royalties and other operating income	-0.3
Cost of sales Operating expenses	Cost of sales	+0.2
	Expenses	+0.4
Operating profit	**-0.0**	

Actual / Forecast rate* (JPY)	2017 Jan - Sep Actual	2018 Jan -Dec Assumption	2018 Jan - Sep Actual
1CHF	113.73	115.00	112.79
1EUR	124.33	133.00	130.93
1USD	111.92	111.00	109.65
1SGD	80.52	84.00	81.81

* Actual: market average exchange rate for the period of Jan - Sep

[Reference]
Historical exchange rate to the JPY





Overview of Development Pipeline

CHUGAI PHARMACEUTICAL CO., LTD.
Department Manager of R&D Portfolio Management Dept., Project & Lifecycle Management Unit
Dr. Minoru Hirose

October 24, 2018

Overview of Development Pipeline

Innovation all for the patients

CHUGAI

Roche A member of the Roche group

Projects under Development (1) (as of October 24, 2018)

	Phase I	Phase II	Phase III		Filed
Oncology	**CKI27** - solid tumors **GC33 (RG7686) / codrituzumab** - HCC★ **ERY974** - solid tumors **RG7421 / cobimetinib** - solid tumors **RG7802** - solid tumors **RG7828 / mosunetuzumab** - hematologic tumors	**RG6268 / entrectinib** - NSCLC - solid tumors	**RG3502 / Kadcyla** - breast cancer (adjuvant) **RG435 / Avastin** - RCC - HCC **RG7440 / ipatasertib** - prostate cancer - breast cancer **RG7596 / polatuzumab vedotin** - DLBCL **RG6264** - breast cancer (Fixed-dose combination, subcutaneous injection)	**AF802 (RG7853) / Alecensa** - NSCLC★ (adjuvant) **RG7446 / Tecentriq** - NSCLC (adjuvant) - SCLC - urothelial carcinoma - MIUC (adjuvant) - RCC - RCC (adjuvant) - breast cancer - early breast cancer★ - ovarian cancer - prostate cancer - HCC - HNC (adjuvant)	**RG7446 / Tecentriq** - NSCLC (1L)
Bone & Joint			**NRD101 / Suvenyl (China)** - knee osteoarthritis /shoulder periarthritis		**ED-71 / Edirol (China)** - osteoporosis
Renal	**EOS789** - hyperphosphatemia				

In principle, completion of first dose is regarded as the start of clinical studies in each phase.

HCC: hepatocellular carcinoma
NSCLC: non-small cell lung cancer
SCLC: small cell lung cancer
MIUC: muscle invasive urothelial carcinoma
RCC: renal cell carcinoma
DLBCL: diffuse large B-cell lymphoma
HNC: head and neck carcinoma

Letters in orange: in-house projects
★: Projects with advances in stages since July 26, 2018
★: Multinational study managed by Chugai

Overview of Development Pipeline

Innovation all for the patients

CHUGAI

Roche A member of the Roche group

Projects under Development (2) (as of October 24, 2018)

	Phase I	Phase II	Phase III	Filed
Autoimmune	**RG7845 / fenebrutinib** - rheumatoid arthritis		**MRA (RG1569) / Actemra** - systemic sclerosis **SA237 (RG6168) / satralizumab** - NMOSD ★	
Neurology	**RG7935 / prasinezumab** - Parkinson's disease **GYM329 (RG70240)** - neuromuscular disease★	**RG7916 / risdiplam** - spinal muscular atrophy	**RG1450 / gantenerumab** - Alzheimer's disease **RG7412 / crenezumab** - Alzheimer's disease **RG6206** - DMD (PII/III)	
Others	**PCO371** - hypoparathyroidism **RG7716** - wAMD **AMY109** - endometriosis	**CIM331 / nemolizumab*** - pruritus in dialysis patients **SKY59 (RG6107)** - paroxysmal nocturnal hemoglobinuria (PI/II)	**RG7716 / faricimab** - DME★	**ACE910 (RG6013) / Hemlibra (JP/EU)** - hemophilia A (non-inhibitor)

In principle, completion of first dose is regarded as the start of clinical studies in each phase.
wAMD: wet age-related macular degeneration
DME: diabetic macular edema
DMD: Duchenne muscular dystrophy
NMOSD: neuromyelitis optica spectrum disorder

Letters in orange: in-house projects
★: Projects with advances in stages since July 26, 2018
★: Multinational study managed by Chugai

* Atopic dermatitis is under development by licensees [Galderma (overseas) and Maruho (Japan)]

Innovation all for the patients
CHUGAI
Roche A member of the Roche group

Development Status (1)

In-house

ACE910 / Hemlibra®

Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks.

Approved in October 2018 (US)*

* Additional dosing options of every two weeks or every four weeks in adults and children with hemophilia A with factor VIII inhibitors are also approved.

In-licensed

RG7159 / Gazyva®

CD20-positive follicular lymphoma

Launched in August 2018

In-licensed

RG1273 / Perjeta ®

Neoadjuvant and adjuvant therapy for HER2-positive early breast cancer

Approved in October 2018

Innovation all for the patients
CHUGAI
Roche A member of the Roche group

Development Status (2)

In-house

AF802 / Alecensa®

ALK positive NSCLC (adjuvant)

Started global Phase 3 study (ALINA) in August 2018

In-licensed

RG7446 / Tecentriq®

<u>Early breast cancer* entered in the pipeline (Phase 3)</u>

Triple negative breast cancer (adjuvant)

Started global Phase 3 study (IMpassion030) in August 2018

*Triple negative breast cancer defined as "early breast cancer"

In-licensed

RG7716 / faricimab

Diabetic macular edema

Started global Phase 3 study (YOSEMITE) in September 2018

In-house

GYM329 (RG70240)

Neuromuscular disease

Started Phase 1 study in October 2018

Innovation all for the patients
CHUGAI
Roche A member of the Roche group

Other Progress (1)

In-house

AF802 / Alecensa®

ALK positive advanced NSCLC (1L)

Approved in August 2018 (China)

In-licensed

Rituxan®

CD20-positive chronic lymphocytic leukemia

Filed in August 2018

In-licensed

RG1450 / gantenerumab

Early Alzheimer's disease

Started global Phase 3 study (GRADUATE2) in July 2018

Innovation all for the patients
CHUGAI
Roche A member of the Roche group

Other Progress (2)

In-licensed

RG7596 / polatuzumab vedotin

Relapsed / refractory DLBCL

Started Phase 2 study in October 2018 (JP)

In-house

OWL833 / Oral GLP-1 agonist

Type 2 diabetes

License agreement* with Eli Lilly for global development and marketing in September 2018

* This transaction is subject to potential competition authority clearances and other customary closing conditions.

Innovation all for the patients

CHUGAI

Roche A member of the Roche group

SA237 / satralizumab SAkuraSky study

Neuromyelitis optica spectrum disorder (NMOSD)

Data from Phase 3 study presented at the Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2018

- Satralizumab patient group*1 showed a statistically significant reduction of the risk of relapse by 62% in patients with NMOSD, achieving the primary endpoint *2
- Results from subgroup analysis indicated the reduction of the risk of relapse in NMOSD patients with / without anti-aquaporin-4(AQP4) antibody, respectively
  - anti-AQP4 Ab positive group : 79% reduction ([Relapse free rate] week48: 91.5%, week96: 91.5%)
  - anti-AQP4 Ab negative group : 34% reduction ([Relapse free rate] week48: 84.4%, week96: 56.3%)
- Favorable safety profile of satralizumab was confirmed



*1 Add on immunosuppressive therapy

*2 Time to first protocol-defined relapse adjudicated by an independent review committee in the double-blind period

Source: ECTRIMS 2018 presentation materials

Innovation all for the patients

CHUGAI

Roche A member of the Roche group

Results of Clinical Trials / Conference (1)

In-licensed

RG7446 / Tecentriq®

Results of IMpower132 / 133 studies (Phase 3) presented at the 2018 World Conference on Lung Cancer (WCLC) in September 2018

<u>IMpower132: non-squamous, NSCLC (1L)</u>

Tecentriq + chemotherapy versus chemotherapy

- median PFS (co-primary endpoint met)
  7.6 months vs 5.2 months; HR=0.60 (95% CI: 0.49-0.72; p<0.0001)
- median OS (co-primary endpoint was not met at this interim analysis)
  18.1 months vs 13.6 months; HR=0.81 (95% CI: 0.64-1.03; p=0.0797)

<u>IMpower133: SCLC (1L)</u>

Tecentriq + chemotherapy versus chemotherapy

- median OS (co-primary endpoint met)
  12.3 months vs 10.3 month; HR=0.70 (95% CI: 0.54-0.91; p=0.0069)
- median PFS (co-primary endpoint met)
  5.2 months vs 4.3 months; HR=0.77 (95% CI: 0.62-0.96; p=0.017)

OS=overall survival; PFS=progression-free survival

Results of Clinical Trials / Conference (2)

Results of IMpassion130 study (Phase 3) presented at the European Society for Medical Oncology (ESMO) in October 2018

<u>IMpassion130: Triple Negative Breast Cancer (1L)</u>

Tecentriq + chemotherapy versus chemotherapy

- median PFS (co-primary endpoint met)
  [ITT] 7.2 months vs 5.5 months; HR=0.80 (95% CI: 0.69-0.92; p=0.0025)
  [PD-L1+] 7.5 months vs 5.0 months; HR=0.62 (95% CI: 0.49-0.78; p<0.0001)

- median OS (co-primary endpoint was not met at this interim analysis)
  [ITT] 21.3 months vs 17.6 months; HR=0.84 (95% CI: 0.69-1.02; p=0.084)
  [PD-L1+] 25.0 months vs 15.5 months; HR=0.62 (95% CI: 0.45-0.86)

ITT=intention to treat

Results of Clinical Trials / Conference (3)

Innovation all for the patients
CHUGAI
Roche A member of the Roche group

In-licensed

RG6268 / entrectinib

Results of integrated analysis on Phase 1/2 studies* presented at the 2018 World Conference on Lung Cancer (WCLC) in September 2018

ROS1 fusion positive NSCLC

- ORR: 77.4%
- median DOR: 24.6 months
- intracranial ORR: 55.0%, 11 out of 20 patients

Results of integrated analysis on Phase 1/2 studies* presented at the European Society for Medical Oncology (ESMO) in October 2018

NTRK fusion positive solid tumors

- ORR: 57.4%
- median DOR: 10.4 months
- intracranial ORR: 54.5%

* STARTRK- 1/2, ALKA-372-001

ORR=objective response rate; DOR=duration of response

Overview of Development Pipeline

Innovation all for the patients

CHUGAI

Roche A member of the Roche group

Projected Submissions (Post PoC NMEs and Products)

as of October 24, 2018

Filed

- TECENTRIQ (RG7446) NSCLC (1L)
- EDIROL (ED-71) Osteoporosis (China)
- HEMLIBRA (ACE910/RG6013) Hemophilia A non-inhibitor (JP/EU)

NME: in-house / in-licensed; line extension

NSCLC: non-small cell lung cancer
RCC: renal cell carcinoma
SCLC: small cell lung cancer
MIUC: muscle invasive urothelial carcinoma
HCC: hepatocellular carcinoma
HNC: head and neck carcinoma
DLBCL: diffuse large B-cell lymphoma
NMOSD: neuromyelitis optica spectrum disorder
FDC: fixed-dose combination
sc: subcutaneous injection

2018

- ACTEMRA (MRA) Systemic Sclerosis
- TECENTRIQ (RG7446) Breast Cancer
- AVASTIN (RG435) RCC
- TECENTRIQ (RG7446) RCC

2019

- satralizumab (SA237/RG6168) NMOSD
- SUVENYL (NRD101) Knee Osteoarthritis /Shoulder Periarthritis (China)
- entrectinib (RG6268) Solid tumors (NTRK+)
- entrectinib (RG6268) NSCLC (ROS1+)
- TECENTRIQ (RG7446) SCLC

2020

- KADCYLA (RG3502) Breast Cancer (adjuvant)
- TECENTRIQ (RG7446) Ovarian Cancer
- risdiplam (RG7916) Spinal Muscular Atrophy
- TECENTRIQ (RG7446) MIUC (adjuvant)
- RG6206 Duchenne Muscular Dystrophy
- TECENTRIQ (RG7446) NSCLC (adjuvant)
- ipatasertib (RG7440) Breast Cancer

2021 and beyond

- ipatasertib (RG7440) Prostate Cancer
- TECENTRIQ (RG7446) HNC (adjuvant)
- nemolizumab* (CIM331) Pruritus in Dialysis Patients
- AVASTIN (RG435) HCC
- faricimab (RG7716) Diabetic Macular Edema
- TECENTRIQ (RG7446) HCC
- crenezumab (RG7412) Alzheimer's Disease
- TECENTRIQ (RG7446) Prostate Cancer
- gantenerumab (RG1450) Alzheimer's Disease
- TECENTRIQ (RG7446) Early Breast Cancer
- ALECENSA (AF802/RG7853) NSCLC (adjuvant)
- TECENTRIQ (RG7446) RCC (adjuvant)
- RG6264 (FDC, sc) Breast cancer
- TECENTRIQ (RG7446) Urothelial Carcinoma
- polatuzumab vedotin (RG7596) DLBCL

*Atopic dermatitis is under development by licensees [Galderma (overseas) and Maruho (Japan)]

Contacts: Corporate Communications Dept.

Media Relations Group

Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607
e-mail: pr@chugai-pharm.co.jp

Tomoko Shimizu, Hiroshi Araki, Chisato Miyoshi, Yayoi Yamada,
Shumpei Yokoyama

Investor Relations Group

Tel: +81 (0)3-3273-0554 Fax: +81 (0)3-3281-6607
e-mail: ir@chugai-pharm.co.jp

Toshiya Sasai, Takayuki Sakurai, Tomoyuki Shimamura,
Sachiyo Yoshimura